Not provided
Not provided
Not provided
Not provided
Not provided
See Detailed Description for termination reason.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study will assess the relative benefit of cabergoline vs carbidopa/levodopa therapy in treating nighttime problems of Parkinson Disease.
The trial was terminated prematurely June 26, 2005 due to the inability to re-supply study drug for the planned number of subjects. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| cabergoline | Drug | |||
| controlled-release levodopa / carbidopa | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| PDSS, UPDRS |
| Measure | Description | Time Frame |
|---|---|---|
| CGI, PGI, Epworth Sleepiness Scale, PDQ-39 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Westmead | New South Wales | Australia | |||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Brisbane |
| Queensland |
| Australia |
| Pfizer Investigational Site | Loc. Camerelle - Pozzilli | IS | Italy |
| Pfizer Investigational Site | Vittoria | Ragusa | Italy |
| Pfizer Investigational Site | Bologna | Italy |
| Pfizer Investigational Site | Bolzano | Italy |
| Pfizer Investigational Site | Naples | Italy |
| Pfizer Investigational Site | Padova | Italy |
| Pfizer Investigational Site | Palermo | Italy |
| Pfizer Investigational Site | Roma | Italy |
| Pfizer Investigational Site | Barcelona | Barcelona | Spain |
| Pfizer Investigational Site | Madrid | Madrid | Spain |
| Pfizer Investigational Site | Oviedo | Principality of Asturias | Spain |
| Pfizer Investigational Site | Seville | Sevilla | Spain |
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077465 | Cabergoline |
| D002230 | Carbidopa |
| ID | Term |
|---|---|
| D004873 | Ergolines |
| D004876 | Ergot Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D008750 | Methyldopa |
| D004295 | Dihydroxyphenylalanine |
| D002395 | Catecholamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D006834 | Hydrazines |
| D002396 | Catechols |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
Not provided
Not provided